HRP20150454T1 - Jediniäśno doziranje apadenozona - Google Patents
Jediniäśno doziranje apadenozona Download PDFInfo
- Publication number
- HRP20150454T1 HRP20150454T1 HRP20150454TT HRP20150454T HRP20150454T1 HR P20150454 T1 HRP20150454 T1 HR P20150454T1 HR P20150454T T HRP20150454T T HR P20150454TT HR P20150454 T HRP20150454 T HR P20150454T HR P20150454 T1 HRP20150454 T1 HR P20150454T1
- Authority
- HR
- Croatia
- Prior art keywords
- unit dose
- amount
- apadenoson
- apadenosone
- mammals
- Prior art date
Links
- 229950001316 apadenoson Drugs 0.000 title claims 6
- FLEVIENZILQUKB-XTWQNQIISA-N chembl1950649 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(C#CC[C@@H]3CC[C@H](CC3)C(=O)OC)=NC(N)=C2N=C1 FLEVIENZILQUKB-XTWQNQIISA-N 0.000 title claims 6
- 239000003937 drug carrier Substances 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 201000000057 Coronary Stenosis Diseases 0.000 claims 2
- 206010011089 Coronary artery stenosis Diseases 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 2
- 239000001509 sodium citrate Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (14)
1. Jedinična doza apadenozona sadrži: (a) apadenozon i (b) farmaceutski prihvatljivi nosač, pri čemu je jedinična doza primjerena parenteralnoj primjeni i daje se pacijentu u pojedinačnoj dozi, koja ne ovisi o težini pacijenta, i pri čemu je količina apadenozona između 76-175 µg.
2. Jedinična doza iz zahtjeva 1, pri čemu je količina prisutnog apadenozona 100 µg.
3. Jedinična doza iz zahtjeva 1, pri čemu je količina prisutnog apadenozona 150 µg.
4. Jedinična doza iz zahtjeva 1, pri čemu farmaceutski nosač uključuje 8-hidroksipropil-ciklodekstrin.
5. Jedinična doza iz zahtjeva 1, pri čemu je pH jedinične doze izabrana između 4,6-5.
6. Jedinična doza iz zahtjeva 5, pri čemu je pH 4,8.
7. Jedinična doza iz zahtjeva 1, pri čemu je volumen jedinične doze izabran između 1-5 mL.
8. Jedinična doza iz zahtjeva 1, pri čemu je volumen jedinične doze 2, 3, 4 ili 5 mL.
9. Jedinična doza iz zahtjeva 1, pri čemu je apadenozon 100 µg apadenozona i pri čemu farmaceutski prihvatljivi nosač uključuje (i) 2% w/v HP-β-CD; (ii) natrijev citratni pufer u količini za namještanje pH jedinične doze na 4,8; (iii) fiziološku otopinu u količini za dobivanje jedinične doze od 1-5 mL.
10. Jedinična doza iz zahtjeva 1, pri čemu je apadenozon 150 µg apadenozona i pri čemu farmaceutski prihvatljivi nosač uključuje (i) 2% w/v HP-β-CD; (ii) natrijev citratni pufer u količini za namještanje pH jedinične doze na 4,8; (iii) fiziološku otopinu u količini za dobivanje jedinične doze od 1-5 mL.
11. Jedinična doza iz zahtjeva 9 ili 10, pri čemu je volumen jedinične doze 2, 3, 4 ili 5 mL.
12. Jedinična doza iz zahtjeva 1 koja je dostupna u unaprijed napunjenoj injekciji.
13. Jedinična doza apadenozona, prema bilo kojem od zahtjeva 1-12, za uporabu u metodi dijagnoze abnormalnosti kod miokardijalne perfuzije koja se sastoji od:
Parenteralne primjene apadenozona kod sisavca;
Izvođenja tehnike za detekciju prisutnosti koronarne arterijske stenoze kod sisavca, za određivanje jačine koronarne arterijske stenoze kod sisavca ili njihova kombinacija.
14. Jedinična doza za uporabu prema zahtjevu 13, pri čemu pacijent teži najmanje 40 kg.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7816908P | 2008-07-03 | 2008-07-03 | |
| US15593709P | 2009-02-27 | 2009-02-27 | |
| PCT/US2009/003939 WO2010002473A1 (en) | 2008-07-03 | 2009-07-02 | Unit dosage of apadenoson |
| EP09773926.2A EP2306971B1 (en) | 2008-07-03 | 2009-07-02 | Unit dosage of apadenoson |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150454T1 true HRP20150454T1 (hr) | 2015-06-19 |
Family
ID=41152021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150454TT HRP20150454T1 (hr) | 2008-07-03 | 2015-04-27 | Jediniäśno doziranje apadenozona |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US20100003193A1 (hr) |
| EP (1) | EP2306971B1 (hr) |
| JP (2) | JP2011526894A (hr) |
| KR (2) | KR20140021726A (hr) |
| CN (1) | CN102119023B (hr) |
| AU (1) | AU2009266317B2 (hr) |
| BR (1) | BRPI0913939A2 (hr) |
| CA (1) | CA2729819C (hr) |
| CY (1) | CY1116283T1 (hr) |
| DK (1) | DK2306971T3 (hr) |
| EA (1) | EA022348B1 (hr) |
| ES (1) | ES2537069T3 (hr) |
| HK (1) | HK1156250A1 (hr) |
| HR (1) | HRP20150454T1 (hr) |
| IL (2) | IL210428A (hr) |
| MX (1) | MX2011000193A (hr) |
| MY (1) | MY161655A (hr) |
| NZ (1) | NZ590489A (hr) |
| PL (1) | PL2306971T3 (hr) |
| PT (1) | PT2306971E (hr) |
| SI (1) | SI2306971T1 (hr) |
| SM (1) | SMT201500123B (hr) |
| WO (1) | WO2010002473A1 (hr) |
| ZA (1) | ZA201100163B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100003193A1 (en) | 2008-07-03 | 2010-01-07 | University Of Virginia Patent Foundation | Unit dosage of apadenoson |
| US20150010472A1 (en) | 2012-02-03 | 2015-01-08 | Adenobio N.V. | Method of using adenosine and dipyridamole for pharmacologic stress testing, with specific compositions, unit dosage forms and kits |
| CN109020881B (zh) * | 2018-06-28 | 2020-04-28 | 新发药业有限公司 | 一种阿帕替尼的制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091171B2 (en) | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
| DE69120840T2 (de) * | 1990-02-21 | 1996-11-21 | United Kingdom Government | Supraleiter auf Thalliumbasis substituiert durch seltene Erden |
| IT1263831B (it) | 1993-01-29 | 1996-09-04 | Paolo Chiesi | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina |
| US7427606B2 (en) | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
| AU778870B2 (en) | 1999-02-01 | 2004-12-23 | University Of Virginia Patent Foundation | Compositions for treating inflammatory response |
| US6232297B1 (en) * | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
| US6322771B1 (en) * | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
| AU2001296006A1 (en) * | 2000-10-23 | 2002-05-06 | Akedo, Jun | Composite structure and method and apparatus for manufacture thereof |
| US6620645B2 (en) * | 2000-11-16 | 2003-09-16 | G.T. Equipment Technologies, Inc | Making and connecting bus bars on solar cells |
| WO2003029264A2 (en) | 2001-10-01 | 2003-04-10 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
| ES2277640T3 (es) * | 2002-02-27 | 2007-07-16 | Ferring Bv | Productos intermedios y metodos para preparar analogos de heptapeptido de oxitocina. |
| ATE381336T1 (de) | 2002-04-10 | 2008-01-15 | Univ Virginia | Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten |
| US6662088B1 (en) * | 2002-06-28 | 2003-12-09 | General Electric Company | Methods and systems for inspecting aircraft fuselage frames |
| US7396825B2 (en) | 2004-05-03 | 2008-07-08 | University Of Virginia Patent Foundation | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy |
| EP1778712B1 (en) * | 2004-08-02 | 2013-01-30 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| EP1729355B1 (en) | 2005-06-03 | 2008-11-19 | STMicroelectronics S.r.l. | Self-aligned process for manufacturing phase change memory cells |
| US7767686B2 (en) | 2006-03-03 | 2010-08-03 | Covidien Ag | Method of using adenosine receptor blockers during tissue ablation |
| DE102006022450A1 (de) | 2006-05-13 | 2007-11-15 | Lanxess Deutschland Gmbh | Wässrige Rußdispersionen für Ink-Jet |
| AU2008276451A1 (en) * | 2007-07-17 | 2009-01-22 | Zalicus Inc. | Treatments of B-cell proliferative disorders |
| TW200905703A (en) * | 2007-07-27 | 2009-02-01 | Delta Electronics Inc | Magnetic device and manufacturing method thereof |
| US20100003193A1 (en) | 2008-07-03 | 2010-01-07 | University Of Virginia Patent Foundation | Unit dosage of apadenoson |
-
2009
- 2009-07-02 US US12/496,949 patent/US20100003193A1/en not_active Abandoned
- 2009-07-02 WO PCT/US2009/003939 patent/WO2010002473A1/en active Application Filing
- 2009-07-02 CA CA2729819A patent/CA2729819C/en active Active
- 2009-07-02 MY MYPI2010006339A patent/MY161655A/en unknown
- 2009-07-02 KR KR1020147003142A patent/KR20140021726A/ko not_active Application Discontinuation
- 2009-07-02 CN CN200980131395.6A patent/CN102119023B/zh not_active Expired - Fee Related
- 2009-07-02 PL PL09773926T patent/PL2306971T3/pl unknown
- 2009-07-02 KR KR1020117002495A patent/KR20110028531A/ko active Application Filing
- 2009-07-02 MX MX2011000193A patent/MX2011000193A/es active IP Right Grant
- 2009-07-02 DK DK09773926.2T patent/DK2306971T3/en active
- 2009-07-02 SI SI200931189T patent/SI2306971T1/sl unknown
- 2009-07-02 NZ NZ590489A patent/NZ590489A/xx not_active IP Right Cessation
- 2009-07-02 PT PT97739262T patent/PT2306971E/pt unknown
- 2009-07-02 BR BRPI0913939A patent/BRPI0913939A2/pt not_active Application Discontinuation
- 2009-07-02 AU AU2009266317A patent/AU2009266317B2/en not_active Ceased
- 2009-07-02 EA EA201100132A patent/EA022348B1/ru not_active IP Right Cessation
- 2009-07-02 ES ES09773926.2T patent/ES2537069T3/es active Active
- 2009-07-02 EP EP09773926.2A patent/EP2306971B1/en active Active
- 2009-07-02 JP JP2011516343A patent/JP2011526894A/ja not_active Withdrawn
-
2011
- 2011-01-02 IL IL210428A patent/IL210428A/en not_active IP Right Cessation
- 2011-01-06 ZA ZA2011/00163A patent/ZA201100163B/en unknown
- 2011-10-07 HK HK11110662.3A patent/HK1156250A1/xx not_active IP Right Cessation
-
2012
- 2012-07-09 US US13/544,364 patent/US20130017153A1/en not_active Abandoned
-
2013
- 2013-08-29 JP JP2013177622A patent/JP2013237702A/ja active Pending
- 2013-12-11 US US14/103,130 patent/US9415058B2/en not_active Expired - Fee Related
-
2015
- 2015-04-27 HR HRP20150454TT patent/HRP20150454T1/hr unknown
- 2015-05-14 CY CY20151100432T patent/CY1116283T1/el unknown
- 2015-05-22 SM SM201500123T patent/SMT201500123B/xx unknown
-
2016
- 2016-05-10 IL IL245577A patent/IL245577B/en active IP Right Grant
- 2016-06-13 US US15/181,235 patent/US9662406B2/en active Active
-
2017
- 2017-05-19 US US15/600,303 patent/US20170252463A1/en not_active Abandoned
-
2018
- 2018-07-25 US US16/045,359 patent/US20190022253A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rodriguez-Torres et al. | Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial | |
| ES2624980T3 (es) | Combinación de dos antivirales para el tratamiento de la hepatitis C | |
| Gerber et al. | New therapeutic strategies in HCV: polymerase inhibitors | |
| Aliter et al. | Thrombin inhibition by argatroban: potential therapeutic benefits in COVID-19 | |
| JP2008527003A5 (hr) | ||
| Samsel et al. | Therapeutic potential of adenosine analogues and conjugates | |
| US20140275237A1 (en) | Beraprost isomer as an agent for the treatment of viral infection | |
| Ruggiero et al. | Endothelial function as a marker of pre-clinical atherosclerosis: assessment techniques and clinical implications | |
| Denning et al. | Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects | |
| HRP20150454T1 (hr) | Jediniäśno doziranje apadenozona | |
| JP2010515081A5 (hr) | ||
| JO3659B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية | |
| WO2006044856A3 (en) | Use of a2a adenosine receptor agonists | |
| JP2019529541A (ja) | 高サイトカイン血症及びウィルス感染の処置の為の肥満細胞安定剤 | |
| De Clercq | The race for interferon‐free HCV therapies: a snapshot by the spring of 2012 | |
| Hunt et al. | What are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals? | |
| AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso | |
| JP2005538190A5 (hr) | ||
| AU2016287580A1 (en) | Compositions and methods for the treatment of viral infection | |
| JP5808772B2 (ja) | 肝細胞内のミトコンドリアの活性化方法 | |
| Shareef et al. | Trends in covid-19 therapeutic modalities: A narrative literature | |
| Hovater et al. | Purinergic signaling in the lumen of a normal nephron and in remodeled PKD encapsulated cysts | |
| Sackner et al. | Endothelial pulsatile shear stress is a backstop for COVID-19 | |
| PT1708721E (pt) | Imagiologia de perfusão miocárdica utilizando agonistas do receptor de adenosina | |
| CN104812383A (zh) | 治疗hcv感染的治疗剂组合 |